skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Oraxol (Code C112000)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Oraxol

Definition: A combination formulation composed of a capsule containing the taxane compound paclitaxel and a tablet containing the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp) inhibitor HM30181A, with potential antineoplastic activity. Upon oral administration of oraxol, the HM30181A moiety binds to and inhibits P-gp, which prevents P-gp-mediated efflux of paclitaxel, therefore enhancing its oral bioavailability. In turn, paclitaxel binds to and stabilizes microtubules, preventing their depolymerization, which results in the inhibition of cellular motility, mitosis, and replication. Altogether, this may result in greater intracellular concentration of paclitaxel, and enhanced cytotoxicity against tumor cells, when compared to the administration of paclitaxel alone. P-gp, encoded by the MDR-1 gene, is a member of the ATP-binding cassette (ABC) superfamily of transmembrane transporters; it prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents.

Display Name: Oraxol

Label: Oraxol

NCI Thesaurus Code: C112000 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL454289  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Paclitaxel-HM30181 Methanesulfonate Monohydrate

External Source Codes: 
PDQ Closed Trial Search ID 754236
PDQ Open Trial Search ID 754236 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C112000
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom